These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 28212926)
41. [Oral disease-modifying agents in relapsing-remitting multiple sclerosis]. Iljicsov A; Pál Z; Simó M Neuropsychopharmacol Hung; 2015 Dec; 17(4):197-205. PubMed ID: 26727724 [TBL] [Abstract][Full Text] [Related]
42. Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. Liebmann M; Korn L; Janoschka C; Albrecht S; Lauks S; Herrmann AM; Schulte-Mecklenbeck A; Schwab N; Schneider-Hohendorf T; Eveslage M; Wildemann B; Luessi F; Schmidt S; Diebold M; Bittner S; Gross CC; Kovac S; Zipp F; Derfuss T; Kuhlmann T; König S; Meuth SG; Wiendl H; Klotz L Brain; 2021 Nov; 144(10):3126-3141. PubMed ID: 34849598 [TBL] [Abstract][Full Text] [Related]
43. Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. Eriksson I; Cars T; Piehl F; Malmström RE; Wettermark B; von Euler M Eur J Clin Pharmacol; 2018 Feb; 74(2):219-226. PubMed ID: 29128972 [TBL] [Abstract][Full Text] [Related]
44. Multiple sclerosis: Dimethyl fumarate is coming of age. Tintoré M; Sastre-Garriga J Nat Rev Neurol; 2016 Aug; 12(8):436-7. PubMed ID: 27448183 [No Abstract] [Full Text] [Related]
45. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Kita M; Fox RJ; Phillips JT; Hutchinson M; Havrdova E; Sarda SP; Agarwal S; Kong J; Zhang A; Viglietta V; Sheikh SI; Seidman E; Dawson KT Mult Scler; 2014 Feb; 20(2):253-7. PubMed ID: 24150778 [TBL] [Abstract][Full Text] [Related]
46. Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate: Significance of CD8 Anagnostouli MC; Velonakis G; Dalakas MC Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34049996 [No Abstract] [Full Text] [Related]
55. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491 [TBL] [Abstract][Full Text] [Related]
56. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Gold R; Arnold DL; Bar-Or A; Hutchinson M; Kappos L; Havrdova E; MacManus DG; Yousry TA; Pozzilli C; Selmaj K; Sweetser MT; Zhang R; Yang M; Potts J; Novas M; Miller DH; Kurukulasuriya NC; Fox RJ; Phillips TJ Mult Scler; 2017 Feb; 23(2):253-265. PubMed ID: 27207449 [TBL] [Abstract][Full Text] [Related]
57. What should we expect from multiple sclerosis therapy? Results of an integrated analysis of delayed-release dimethyl fumarate pivotal trials. Lanzillo R Eur J Neurol; 2017 May; 24(5):661-662. PubMed ID: 28332255 [No Abstract] [Full Text] [Related]
58. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients. Hovi A; Airas L J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874 [No Abstract] [Full Text] [Related]
59. Dimethyl fumarate for ischemic stroke. Kunze R Oncotarget; 2017 Feb; 8(9):14281-14282. PubMed ID: 28209921 [No Abstract] [Full Text] [Related]
60. [Update on Current Care Guideline: Multiple sclerosis]. Remes A; Airas L; Atula S; Färkkilä M; Hartikainen P; Koivisto K; Mäenpää E; Ruutiainen J; Sumelahti ML; Duodecim; 2015; 131(5):500-1. PubMed ID: 26237913 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]